MA32997B1 - Macrolide anti-inflammatoire - Google Patents

Macrolide anti-inflammatoire

Info

Publication number
MA32997B1
MA32997B1 MA34057A MA34057A MA32997B1 MA 32997 B1 MA32997 B1 MA 32997B1 MA 34057 A MA34057 A MA 34057A MA 34057 A MA34057 A MA 34057A MA 32997 B1 MA32997 B1 MA 32997B1
Authority
MA
Morocco
Prior art keywords
inflammatory
macrolide anti
compound
macrolide
diethylaminoethanoyl
Prior art date
Application number
MA34057A
Other languages
Arabic (ar)
English (en)
Inventor
Darko Filic
Leanda Jane Kindon
Caroline Jane Day
Julien Bruno Douillet
Goran Kragol
Zorica Marusic-Istuk
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32997(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA32997B1 publication Critical patent/MA32997B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention porte sur le composé 3'-N-déméthyl-4''-O- (2-diéthylaminoéthanoyl)-6-O-méthyl-9a-aza-9a-homoérythromycine A, répondant à la formule (I) ou un sel de celui-ci, sur des compositions comprenant le composé, sur ses utilisations pour le traitement de maladies inflammatoires dominées par les neutrophiles et sur ses procédés de préparation.
MA34057A 2009-01-30 2010-01-28 Macrolide anti-inflammatoire MA32997B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14860909P 2009-01-30 2009-01-30
PCT/EP2010/050967 WO2010086349A1 (fr) 2009-01-30 2010-01-28 Macrolide anti-inflammatoire

Publications (1)

Publication Number Publication Date
MA32997B1 true MA32997B1 (fr) 2012-01-02

Family

ID=41698466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34057A MA32997B1 (fr) 2009-01-30 2010-01-28 Macrolide anti-inflammatoire

Country Status (23)

Country Link
US (1) US8227428B2 (fr)
EP (1) EP2384333B1 (fr)
JP (1) JP5437394B2 (fr)
KR (1) KR20110099791A (fr)
CN (1) CN102378763A (fr)
AR (1) AR075340A1 (fr)
AU (1) AU2010209732B2 (fr)
BR (1) BRPI1006114A2 (fr)
CA (1) CA2748847A1 (fr)
CL (1) CL2011001829A1 (fr)
CO (1) CO6400226A2 (fr)
DO (1) DOP2011000242A (fr)
EA (1) EA201101139A1 (fr)
ES (1) ES2412059T3 (fr)
IL (1) IL213871A0 (fr)
MA (1) MA32997B1 (fr)
MX (1) MX2011008074A (fr)
PE (1) PE20120220A1 (fr)
SG (1) SG172782A1 (fr)
TW (1) TW201038277A (fr)
UY (1) UY32408A (fr)
WO (1) WO2010086349A1 (fr)
ZA (1) ZA201104653B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51479B (sr) 2005-01-13 2011-04-30 Glaxo Group Limited Makrolidi sa anti-inflamatornim dejstvom
EA201101139A1 (ru) 2009-01-30 2012-03-30 Глэксо Груп Лимитед Противовоспалительный макролид
US20130045939A1 (en) * 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
WO2011131749A1 (fr) * 2010-04-23 2011-10-27 Glaxo Group Limited Nouveaux macrolides à 14 et 15 chaînons pour le traitement de maladies inflammatoires à dominance en neutrophiles
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
KR20190095372A (ko) * 2017-01-13 2019-08-14 토비시 파마슈티칼 컴패니 리미티드 호중구 활성화 조절제
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2021183754A1 (fr) 2020-03-12 2021-09-16 Zoetis Services Llc Azalides immunomodulateurs de trifluorométhyl-aminal

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525051A (en) 1894-08-28 Adjustable chair
US3725385A (en) 1970-11-02 1973-04-03 Abbott Lab Process for the demethylation of 3-amino macrolides
EP0126344A2 (fr) 1983-05-20 1984-11-28 Abbott Laboratories Esters tripeptidiques d'agents thérapeutiques
EP0292352A3 (fr) * 1987-05-06 1988-12-28 Adir Et Compagnie Nouveaux dérivés macrolides, leur procédé de préparation et les compositions pharmaceutiques les contenant
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0895999A1 (fr) 1997-08-06 1999-02-10 Pfizer Products Inc. Macrolides antibiotiques substitués C"-4
HRP980189B1 (en) 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
HUP0201341A3 (en) * 1999-05-18 2003-03-28 Pfizer Prod Inc Novel crystalline forms of a macrolide antibiotic, process for its preparation and pharmaceutical compositions containing it
HRP20010301A2 (en) 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
JP4790263B2 (ja) 2002-07-08 2011-10-12 グラクソ グループ リミテッド 炎症性の疾患および病態を治療する新規な化合物、組成物および方法
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
GB0310986D0 (en) 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
RS51479B (sr) * 2005-01-13 2011-04-30 Glaxo Group Limited Makrolidi sa anti-inflamatornim dejstvom
WO2006077501A2 (fr) 2005-01-13 2006-07-27 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Decladinosyl-macrolides presentant une activite anti-inflammatoire
WO2006106440A1 (fr) 2005-01-14 2006-10-12 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Composes macrolide contenant de la biotine et un groupe a photo-affinite pour l'identification cible de macrolide
EA201101139A1 (ru) 2009-01-30 2012-03-30 Глэксо Груп Лимитед Противовоспалительный макролид

Also Published As

Publication number Publication date
AU2010209732A1 (en) 2011-07-21
MX2011008074A (es) 2011-08-17
ZA201104653B (en) 2012-02-29
CL2011001829A1 (es) 2011-10-14
PE20120220A1 (es) 2012-04-04
AR075340A1 (es) 2011-03-23
US8227428B2 (en) 2012-07-24
EP2384333B1 (fr) 2013-04-17
IL213871A0 (en) 2011-07-31
EA201101139A1 (ru) 2012-03-30
AU2010209732B2 (en) 2012-12-20
US20100197623A1 (en) 2010-08-05
CA2748847A1 (fr) 2010-08-05
DOP2011000242A (es) 2011-09-15
ES2412059T3 (es) 2013-07-10
JP5437394B2 (ja) 2014-03-12
TW201038277A (en) 2010-11-01
UY32408A (es) 2010-07-30
JP2012516304A (ja) 2012-07-19
SG172782A1 (en) 2011-08-29
BRPI1006114A2 (pt) 2018-02-06
CO6400226A2 (es) 2012-03-15
KR20110099791A (ko) 2011-09-08
EP2384333A1 (fr) 2011-11-09
WO2010086349A1 (fr) 2010-08-05
CN102378763A (zh) 2012-03-14

Similar Documents

Publication Publication Date Title
MA32997B1 (fr) Macrolide anti-inflammatoire
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
MA33492B1 (fr) Inhibiteurs de bace
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA32171B1 (fr) Compose heterocyclique
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA41625A (fr) Composés de benzazépine dicarboxamide
MX2010004705A (es) Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA41179A (fr) Composés inhibiteurs de parg
MA46337A (fr) Composé de pyridine
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA32965B1 (fr) Derives de sulfonamides
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
UA107100C2 (xx) Конденсовані гетероароматичні піролідинони як інгібітори syk
WO2009080638A3 (fr) Sulfamides en tant qu'inhibiteurs de zap-70
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA35833B1 (fr) Dérivés de bétuline
MA34599B1 (fr) Compositions pharmaceutiques contenant un inhibiteur dgat1
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale